R0395
 |  |  |
 |
Image
R0395
Sigma
Rapamycin from Streptomyces hygroscopicus
≥95% (HPLC), powder
| Synonym: | 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, AY 22989, Sirolimus |
| CAS Number: | 53123-88-9 |
| Linear Formula: | C51H79NO13 |
| Molecular Weight: | 914.17 |
| MDL number: | MFCD00867594 |
| PubChem Substance ID: | 24899339 |
Description
| Frequently Asked Questions | Live Chat and Frequently Asked Questions are available for this Product. |
| Biochem/physiol Actions | Rapamycin is a macrocyclic triene antibiotic possessing potent immunosuppressant and anticancer activity. It forms a complex with FKBP12 that binds to and inhibits the molecular target of rapamycin (mTOR). mTOR is a member of the phosphoinositide kinase-related kinase (PIKK) family that enhances cellular proliferation via the phosphoinositol 3-kinase/Akt signaling pathway. Inhibition of this pathway by rapamycin blocks downstream elements that result in cell cycle arrest in G1. The effectors of mTOR action include 4EBP1 and S6K1. |
| General description | Rapamycin, a macrocyclic triene antibiotic, possesses immunosuppressant, anti-proliferative, and anti-cancer activity. It complexes with FK-binding protein (FKBP12) and inhibits mTOR (FRAP, RAFT), a member of the phosphoinositide kinase-related kinase (PIKK) family. mTOR enhances phosphoinositol 3-kinase (PI3K)/Akt signaling. Inhibition by rapamycin results in cell cycle arrest in G1. |
Properties
| assay | ≥95% (HPLC) |
| form | powder |
| color | off-white |
| solubility | ethanol: 2 mM |
| DMSO: soluble | |
| Gene Information | human ... FKBP1A(2280) |
| storage temp. | −20°C |
Safety
| Personal Protective Equipment | Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter |
| Safety Statements | 22-24/25 |
| WGK Germany | 2 |
| RTECS | VE6250000 |
References
| reference | Sehgal, S.N. and Bansback, C.C., Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann. N.Y. Acad. Sci. 685, 58-67, (1993) Abstract |
| Mita MM, et al., The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol. Ther. 2(4 Suppl 1), S169-S177, (2003) | |
| Corradetti MN, and Guan KL., Upstream of the mammalian target of rapamycin; do all roads pass through mTOR? Oncogene 25, 6347-6360, (2006) Abstract | |
| Chiang GG, and Abraham RT., Targeting the mTOR signaling network in cancer Trends Mol. Med. 13, 433-442, (2007) Abstract | |
| Foster DA, Toschi A., Targeting mTOR with rapamycin; One dose does not fit all Cell Cycle 2, 8, (2009) | |
| Mita, MM, et al., The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2, S169-S177, (2003) | |
| Shamji, A.F., et al., Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell. 12, 271-280, (2003) | |
| Abraham, R.T., mTOR as a positive regulator of tumor cell responses to hypoxia. Curr. Top. Microbiol. Immunol. 279, 299-319, (2004) |
